Stay updated on Safety of Single Dose UB-221 in Urticaria Clinical Trial

Sign up to get notified when there's something new on the Safety of Single Dose UB-221 in Urticaria Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Safety of Single Dose UB-221 in Urticaria Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    No Change Detected
  4. Check
    3 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.2%
    Check dated 2024-06-13T21:58:29.000Z thumbnail image
  5. Check
    4 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a potential update or revision in the study details related to evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of UB-221 in chronic spontaneous urticaria subjects.
    Difference
    0.2%
    Check dated 2024-06-06T14:33:00.000Z thumbnail image
  7. Check
    25 days ago
    Change Detected
    Summary
    The webpage has been updated to include detailed eligibility criteria for participation in the study, specifying that subjects must be aged 18 or older, able to provide informed consent, and diagnosed with chronic spontaneous urticaria for more than six weeks. Previously, no information was provided under the Participation Criteria section.
    Difference
    13%
    Check dated 2024-05-22T21:03:48.000Z thumbnail image
  8. Check
    47 days ago
    Change Detected
    Difference
    2%
    Check dated 2024-04-30T22:39:39.000Z thumbnail image

Stay in the know with updates to Safety of Single Dose UB-221 in Urticaria Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Safety of Single Dose UB-221 in Urticaria Clinical Trial page.